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Background
Intraductal administration of cytotoxic agents has been
shown to inhibit the development of breast cancer in Her-
2/neu over-expressing mouse and MNU rat models. This
dose escalation study was performed to demonstrate the
safety of this approach in women prior to mastectomy.
Methods
The study was performed in Cancer Hospital, Chinese
Academy of Medical Sciences, Beijing, China where the
standard of care includes a long preoperative hospital stay
prior to mastectomy. Two drugs, pegylated liposomal
doxorubicin (PLD) and carboplatin (C) were adminis-
tered at 3 dose levels (PLD: 10,20,50 mg and carboplatin
60,120,300 mg) with the highest dose approximating the
clinical intravenous dose. There were five subjects in each
group with 15 subjects treated with each drug. Study drug
was administered once per subject. Upon obtaining
informed consent, subjects underwent a local nipple
block and cannulation of 5–8 ducts with intraductal
instillation of the drug. Venous blood samples were
obtained for pharmacokinetic analysis. The total dosage
was divided by the number of cannulated ducts to yield a
dose per duct. The breast was removed surgically as
planned 2–5 days post treatment and the treated ducts
were marked to enable identification on pathological
evaluation.
Results
Intraductal administration was generally well-tolerated
with mild, transient breast discomfort upon administra-
tion associated with the rate of infusion. Clinically signif-
icant laboratory adverse events were limited to decreases
in hemoglobin following mastectomy, consistent with
blood loss. Neither leucopenia nor thrombocytopenia
were observed in the study. In the carboplatin arm, three
women at the 300 mg dose experienced mild nausea and
vomiting. In the PLD arm most women had mild ery-
thema and swelling of the breast over the 72 hours follow-
ing the drug administration while the women receiving
the highest dose experienced local erythema until the time
of surgery.
Pharmacokinetic analysis showed that carboplatin rapidly
entered systemic circulation with an early peak time
(tmax~30 min) with a resultant PUF AUC (area under the
curve) consistent with the Calvert Formula using esti-
mated GFR. Total plasma doxorubicin had delayed peak
concentration times (tmax >36 hours) with a linear dose
response and peak concentrations substantially lower
than expected from equivalent IV dosing. No doxorubici-
nol metabolite was detected in the plasma.
Pathological examination showed the drugs were widely
distributed throughout the ductal systems reaching termi-
nal duct lobular units, and there was a significant
although variable dose-related epithelial cell loss in ducts
with dye indicating drug effect. While dye was seen in or
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near the cancer areas, the effect of drug treatment on the
disease could not be distinguished.
Conclusion
This study demonstrates that cytotoxic drugs can be easily
administered into breast ducts with minimal toxicity.
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